Abstract
Background: Hyperammonemia is an infrequent adverse drug reaction (ADR) of chemotherapy. A few cases of 5-fluorouracil (5-FU) related hyperammonemia have been reported. However, hyperammonemia induced by capecitabine, an oral prodrug of 5-FU, has not been reported till date.
Case Report: A patient with colon cancer was treated with CapeOx (oxaliplatin 200mg, day 1; capecitabine 1.5g bid, days 1-14). On the fifth day of first cycle chemotherapy, she developed hyperammonemia (245 µmol/L) and psychiatric symptoms. The serum 5-FU level (3.2µg/L) was lower than normal. When the patient recovered with drug treatment, capecitabine was restarted at a lower dose (1g bid). Hyperammonemia (98µmol/L) and psychiatric symptoms reappeared after three days. Serum 5-FU remained at a low level (4.6µg/L). This case highlighted the possibility of hyperammonemia induced by capecitabine. Case reports such as these would make physicians more aware of rare ADR and what to be done in such case.
Keywords: Hyperammonemia, capecitabine, adverse drug reaction, colon cancer, 5-fluorouracil, chemotherapy.
Graphical Abstract
Current Drug Safety
Title:A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer
Volume: 13 Issue: 1
Author(s): Wentong Fang, Yuanyuan Fu and Jifu Wei*
Affiliation:
- Department of Pharmacy, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu,China
Keywords: Hyperammonemia, capecitabine, adverse drug reaction, colon cancer, 5-fluorouracil, chemotherapy.
Abstract: Background: Hyperammonemia is an infrequent adverse drug reaction (ADR) of chemotherapy. A few cases of 5-fluorouracil (5-FU) related hyperammonemia have been reported. However, hyperammonemia induced by capecitabine, an oral prodrug of 5-FU, has not been reported till date.
Case Report: A patient with colon cancer was treated with CapeOx (oxaliplatin 200mg, day 1; capecitabine 1.5g bid, days 1-14). On the fifth day of first cycle chemotherapy, she developed hyperammonemia (245 µmol/L) and psychiatric symptoms. The serum 5-FU level (3.2µg/L) was lower than normal. When the patient recovered with drug treatment, capecitabine was restarted at a lower dose (1g bid). Hyperammonemia (98µmol/L) and psychiatric symptoms reappeared after three days. Serum 5-FU remained at a low level (4.6µg/L). This case highlighted the possibility of hyperammonemia induced by capecitabine. Case reports such as these would make physicians more aware of rare ADR and what to be done in such case.
Export Options
About this article
Cite this article as:
Fang Wentong , Fu Yuanyuan and Wei Jifu *, A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886312666170807102132
DOI https://dx.doi.org/10.2174/1574886312666170807102132 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Recent Advances and Novel Approaches for Nose to Brain Drug Delivery for Treatment of Migraine
Drug Delivery Letters Nitroxides as Cancer Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design In vitro Evaluation of Helicobacter pylori Inhibition by Artemisia absinthium and Eugenia caryophyllata Extracts with Black Seeds Honey
The Natural Products Journal Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma
Current Cancer Drug Targets Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies
Current Medicinal Chemistry MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Current Medicinal Chemistry Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Chemoinformatic Analysis of Biologically Active Macrocycles
Current Topics in Medicinal Chemistry